Rational Approach to Improving Cardiac Arrhythmia Therapy. Rational Approach to Improving Cardiac Arrhythmia Therapy
|
|
- Bernard Price
- 6 years ago
- Views:
Transcription
1 Rational Approach to Improving Cardiac Arrhythmia Therapy Rational Approach to Improving Cardiac Arrhythmia Therapy Stanley Nattel, MD Stanley Nattel, MD DEDICATED TO THE MASTER OF RATIONAL THERAPEUTICS SN.23 SENAC: Cinchona bark for palpitations (1749) FREY: On atrial fibrillation in humans and Its Elimination by Quinidine (1918) Ventricular fibrillation as an electrical accident Lidocaine to treat ventricular ectopy post-mi A B PVC's PRE-LIDOCAINE C 2 sec. POST-LIDOCAINE VT LIDOCAINE IV WIGGERS CJ, Am Heart J 2: , 194 GIANELLY R et al, NEJM 277: , 1967
2 Total suppression of ventricular arrhythmias by encainide Oral flecainide acetate for the treatment of ventricular arrhythmias RODEN DM et al, NEJM 32 : , 198 ANDERSON JL et al, NEJM 35 : , 1981 Odds ratio for total mortality 1-48 hr post-mi Effects of class 1C antiarrhythmias on post-mi mortality CAST MACMAHON S et al, JAMA 26: , 1988 NEJM 321:46-412, 1989 Effects of class 1C antiarrhythmias on post-mi mortality Effects of class 1C antiarrhythmias on post-mi mortality CAST CAST II CAST CAST II NEJM 321:46-412, 1989 CAST II Investigators, NEJM 327 : , 1992 NEJM 321:46-412, 1989 CAST II Investigators, NEJM 327 : , 1992
3 Meta-analysis of quinidine effects on mortality in AF patients OK, Class I drugs are bad. Class III is the future. From first class to third class: recent upheaval in antiarrhythmic therapy lessons from clinical trials. Lazzara R. COPLEN et al, Circulation 82 : , 199 LAZZARA R, AJC 78(4A):28-33, 1996 Effects of a pure class III drug on post-mi mortality Something doesn t fit! WALDO AL et al, Lancet 348:7-12, 1996 Something doesn t fit! Focus on a specific arrhythmia Look for the finding that doesn t fit. THAT is the clue to great discoveries!! Prevalence % Age-Related Prevalence of AF Framingham CHS Rochester Western Australia Age FEINBERG WM ET AL, Arch Intern Med 1995; 155:
4 New antiarrhythmic drug development approaches for AF Problem of ventricular proarrhythmia I Kur I Ks Atrium Novel ion channel targets Ventricle I Ks Agrandissement des 3 dérivations synchrones montrant en D III les torsades de pointes. DESSERTENNE, Arch. des Mal.du Cœur 1966; 59: and strategy of atrial-selective therapies I Kur I Ks Atrium K + channel blockers with atrial selectivity I Ks Ventricle Agrandissement des 3 dérivations synchrones montrant en D III les torsades de pointes. DESSERTENNE, Arch. des Mal.du Cœur 1966; 59: Atrial-selective therapies I Kur I Kur (ultrarapid delayed rectifier) is Atrial-specific in Man Atrial cell Ventricular cell XX Atrium I Kur I Ks I Ks Ventricle Agrandissement des 3 dérivations synchrones montrant en D III les torsades de pointes. DESSERTENNE, Arch. des Mal.du Cœur 1966; 59: LI ET AL, Circ Res. 1996; 78:
5 I Kur (ultrarapid delayed rectifier) is Atrial-specific in Man Atrial cell Ventricular cell HUMAN ATRIAL MUSCLE 3 µm XEN-D11 5 mv 5 mv 1 µm XEN-D11 1 ms 1 µm XEN-D11 3 µm XEN-D11 VARRO ET AL, 27 ERP (ms) 12 RAA BCL (ms) ERP 3 (ms) 2 RV Efficacy of an I Kur blocker (Xen-D11) on atrial and ventricular ERPs in AT-remodeled dogs ERP (ms) ERP (ms).3mg/kg 12 1mg/kg 3mg/kg BCL (ms) ERP 5 (ms) BCL (ms) Post drug LI ET AL, Circ Res. 1996; 78: ms HUMAN VENTRICULAR MUSCLE.3mg/kg 1mg/kg 3mg/kg.3mg/kg 1mg/kg 3mg/kg Shiroshita-Takeshita et al, Heart Rhythm 3: S183, 26. DAF (s) 12 Efficacy of an I Kur blocker (Xen-D11) on AF in dogs with atrial tachycardia remodeling (%) 1 New antiarrhythmic drug development approaches for AF Targeting the substrate.3mg/kg 1mg/kg 3mg/kg.3mg/kg 1mg/kg 3mg/kg :p<.5, :p<.1vs baseline Shiroshita-Takeshita et al, Heart Rhythm 3: S183, 26. Determinants of Arrhythmia Mechanisms in AF: Role of Remodeling Determinants of Arrhythmia Mechanisms in AF: Prevention of Remodeling Substrate Trigger Ectopic activity Substrate Trigger Ectopic activity XX XX Remodeling Remodeling Reentry Atrial Fibrillation Reentry Atrial Fibrillation
6 Effects of electrically maintained AF on spontaneous AF maintenance when stimulation stopped Atrial Myocyte Adaptation to Ca 2+ Loading Sinus rhythm (6/min) 1-fold rate increase AF (4-6/min) Cellular Ca 2+ loading Threat to cell viability WIJFFELS MCEF, Kirchhof CJHJ, Dorland R, et al. Circulation 1995; 92: SN.22 Atrial Myocyte Adaptation to Ca 2+ Loading Atrial Myocyte Adaptation to Ca 2+ Loading Sinus rhythm (6/min) 1-fold rate increase AF (4-6/min) Sinus rhythm (6/min) 1-fold rate increase AF (4-6/min) Cellular Ca 2+ loading Cellular Ca 2+ loading Threat to cell viability minutes Threat to cell viability minutes hours - days mrna inactivation inactivation protein SN.22 SN.22 Atrial Myocyte Adaptation to Ca 2+ Loading Sinus rhythm (6/min) 1-fold rate increase AF (4-6/min) Cellular Ca 2+ loading Threat to cell viability minutes inactivation + hours - days mrna protein Patients without Recurrence (%) Superiority of Amiodarone in AF Amiodarone (n = 21) Propafenone (n = 11) Sotalol (n = 11) Days of Follow-up SN.22 APD RP SN.23 ROY et al, N Engl J Med 2; 342: KOCHIADAKIS et al, Heart 2; 84: 1-7
7 Effects of Antiarrhythmic Drugs on AF Effects of Antiarrhythmic Drugs on AF (s) (s) Vulnerability (%) Vulnerability (%) SN.23 P<.5, P<.1 vs CTL SHINAGAWA et al, Circulation, 17: , 23 SN.23 P<.5, P<.1 vs CTL SHINAGAWA et al, Circulation, 17: , 23 Effects of Antiarrhythmic Drugs on AF Effects of Remodeling on α 1c Subunit Expression (s) Vulnerability (%) SN P<.5, P<.1 vs CTL SHINAGAWA et al, Circulation, 17: , 23 A B C D Pace Amio Amio + Pace Dof Dof + Pace Flec Flec + Pace E Area x OD normalized ND = no drug F = flecainide NS NS NS A = amiodarone D = dofetilide NS Pacing SHINAGAWA et al, Circulation, 17: , 23 Effects of Remodeling on α 1c Subunit Expression Effects of Remodeling on α 1c Subunit Expression A Pace E 1.2 ND = no drug F = flecainide A = amiodarone D = dofetilide A Pace E 1.2 ND = no drug F = flecainide A = amiodarone D = dofetilide B C Amio Amio + Pace Dof Dof + Pace Area x OD normalized NS NS NS NS B C Amio Amio + Pace Dof Dof + Pace Area x OD normalized NS NS NS NS D Flec Flec + Pace. Pacing D Flec Flec + Pace. Pacing SHINAGAWA et al, Circulation, 17: , 23 SHINAGAWA et al, Circulation, 17: , 23
8 Effects of Various Agents on Ca v 1.2 Expression Effects of Various Agents on Ca v 1.2 Expression (AU) 1.5 (AU) 1.5 Ca v 1.2 GAPDH NP ATP SIM OXY PRO VitC VitC&E 1..5 Ca v 1.2 GAPDH NP ATP SIM OXY PRO VitC VitC&E 1..5 NP ATP SIM OXY PRO VitCVitC&E NP ATP SIM OXY PRO VitCVitC&E :p<.5 vs ATP, :p<.1 vs ATP :p<.5 vs ATP, :p<.1 vs ATP Can we identify new antiarrhythmic approaches that work by preventing atrial-tachycardia remodeling? Can we identify new antiarrhythmic approaches that work by preventing atrial-tachycardia remodeling? 3 DAF (s) 1 (%) 3 DAF (s) 1 (%) Sinus rhythm maintenance NP ATP SIM NP ATP SIM 1 NP ATP SIM NP ATP SIM Shiroshita-Takeshita et al, Circulation 24;11: Shiroshita-Takeshita et al, Circulation 24;11: Siu et al, Am J Cardiol 23;92: Remodeling Induces Two Clinically Relevant AF Substrates: Atrial-tachycardia Remodeling and Structural Remodeling Atrial tachycardia remodeling -induced remodeling produces a structural substrate for AF Histology Epicardial maps LI et al, Circulation 1999; 1:87-95 AF-induced remodeling Heart disease-induced remodeling LI et al, ENG et al, Res. 1997;8: Circulation 1999; 1:87-95
9 Can Inhibiting Ang-II Formation Prevent Development of the Substrate for AF? Can Inhibiting Ang-II Formation Prevent Development of the Substrate for AF? % Connective tissue (s) % Connective tissue (s) # 3 2 # 1 1 E = enalapril; HI=hydralazine/isosorbide induces fibrosis and increases CTL +E +HI LI D et al, Circulation 14: , 21 E = enalapril; HI=hydralazine/isosorbide Enalapril attenuates fibrosis and increases CTL +E +HI LI D et al, Circulation 14: , 21 Can Inhibiting Ang-II Formation Prevent Development of the Substrate for AF? ACE antagonism and clinical AF in LV dysfunction % Connective tissue (s) AF in post-mi patients with LVD AF in SOLVD patients 9 8 enalapril AF occurrence SR maintenance placebo # 1 E = enalapril; HI=hydralazine/isosorbide Vasodilator therapy does not mimic enalapril effects CTL +E +HI LI D et al, Circulation 14: , 21 Pedersen et al, Circulation 1999; 1: Vermes et al, Circulation 23; 17: Atrial tachycardia remodeling: AF Begets AF New antiarrhythmic drug development approaches for AF Normal AP Substrate-selective ion channels AT AP SN.21 Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Circulation 1995; 92:
10 Atrial tachycardia remodeling: AF Begets AF Constitutive that is enhanced by atrial tachycardia? Changes in outward currents Pre-TQ CONTROL AT Normal AP AT AP Tertiapin-Q (Specific blocker) TQ-sens SN.21 Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Circulation 1995; 92: Cha TJ et al, Circulation. 26;113: Effects of block on APD and tachyarrhythmia Effects of block on APD and tachyarrhythmia CONTROL AT CONTROL AT Cha TJ et al, Circulation. 26;113: Cha TJ et al, Circulation. 26;113: Atrial-selective therapies Effects of an -selective blocker (NIP 151) on AF in two canine models XX Atrium I Kur I Ks Vagal AF compound AF termination dose prevention of NO. Time plasma conc. (μg/kg/min) terminated sec AF reinduction (ng/ml) vehicle 1/ /1 2 2/ NIP /5 5± 22±6 1/4 1 5/5 372±38 16±4 4/5 dofetilide 3 1/3 558 n.d /1 1 / Agrandissement des 3 dérivations synchrones montrant en D III les torsades de pointes. DESSERTENNE, Arch. des Mal.du Cœur 1966; 59: Ventricle I Ks Aconitine-induced AF AF termination dose compound NO. Time (mg/kg) terminated sec vehicle /3 -.1 / /3 67 NIP / /3 55 Hashimoto N et al. Circulation. ;112:II-191.
11 Vagal AF Effects of an -selective blocker (NIP 151) on AF in two canine models compound AF termination dose prevention of NO. Time plasma conc. (μg/kg/min) terminated sec AF reinduction (ng/ml) vehicle 1/ /1 2 2/ NIP /5 5± 22±6 1/4 1 5/5 372±38 16±4 4/5 Collateral effects on extra-atrial (SAN) and 3 1/3 558 n.d /1 dofetilide 1 / extracardiac (GI and GU systems) need to be avoided Aconitine-induced AF AF termination dose compound NO. Time (mg/kg) terminated sec vehicle /3 -.1 / /3 67 NIP / /3 55 Hashimoto N et al. Circulation. ;112:II-191. We have come a long way We have come a long way But we do hope to get there! There is still a considerable way to go 5 mv 9 1 µm XEN-D11 8 HUMAN ATRIAL MUSCLE 7 3 µm XEN-D11 3 µm XEN-D µm XEN-D11 VARRO ET AL, ms HUMAN VENTRICULAR MUSCLE 5 mv CTL # +E +H/I MGH McGill MGH McGill Thank You St. Paul s Dalhousie St. Paul s Dalhousie
Atrial fibrillation (AF) is the most common cardiac
Effects of Antiarrhythmic Drugs on Fibrillation in the Remodeled Atrium Insights Into the Mechanism of the Superior Efficacy of Amiodarone Kaori Shinagawa, MD; Akiko Shiroshita-Takeshita, MD; Gernot Schram,
More informationDrugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification
Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationPHARMACOLOGY OF ARRHYTHMIAS
PHARMACOLOGY OF ARRHYTHMIAS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 27, 2012 Materials on: Exam #5 Required reading: Katzung, Chapter 14 1 CARDIAC ARRHYTHMIAS Abnormalities
More informationAntiarrhythmic Drugs
Antiarrhythmic Drugs DR ATIF ALQUBBANY A S S I S T A N T P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y C O N S U L T A N T C A R D I O L O G Y & I N T E R V E N T I O N A L E P A C H D /
More informationAtrial fibrillation: the remodelling phenomenon
European Heart Journal Supplements (2003) 5 (Supplement H), H1 H7 Atrial fibrillation: the phenomenon G.L. Botto, M. Luzi and A. Sagone Department of Cardiology, St Anna Hospital, Como, Italy KEYWORDS
More informationAtrial fibrillation: the remodelling phenomenon
European Heart Journal Supplements (2003) 5 (Supplement H), H1 H7 Atrial fibrillation: the phenomenon G.L. Botto, M. Luzi and A. Sagone Department of Cardiology, St Anna Hospital, Como, Italy KEYWORDS
More informationThe mechanism of the cardiac arrhythmias Norbert Jost, PhD
The mechanism of the cardiac arrhythmias Norbert Jost, PhD Department of Pharmacology & Pharmacotherapy, University of Szeged Division for Cardiovascular Pharmacology, Hungarian Academy of Sciences Szeged,
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationDECLARATION OF CONFLICT OF INTEREST. Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical
DECLARATION OF CONFLICT OF INTEREST Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical ESC Congress Paris, France August 27-31, 2011 Risk & Complications of AADs for Rhythm
More informationEvolving pharmacologic antiarrhythmic treatment targets Ready for clinical practice?
Evolving pharmacologic antiarrhythmic treatment targets Ready for clinical practice? David O. Arnar MD PhD EMPH Landspitali The National University Hospital of Iceland, Reykjavik Disclosures Consultant
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationThe Role of ACEI and ARBs in AF prevention
The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and
More informationPediatrics ECG Monitoring. Pediatric Intensive Care Unit Emergency Division
Pediatrics ECG Monitoring Pediatric Intensive Care Unit Emergency Division 1 Conditions Leading to Pediatric Cardiology Consultation 12.7% of annual consultation Is arrhythmias problems Geggel. Pediatrics.
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More informationThe most common. hospitalized patients. hypotension due to. filling time Rate control in ICU patients may be difficult as many drugs cause hypotension
Arrhythmias in the critically ill ICU patients: Approach for rapid recognition & management Objectives Be able to identify and manage: Atrial fibrillation with a rapid ventricular response Atrial flutter
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationAmiodarone Prescribing and Monitoring: Back to the Future
Amiodarone Prescribing and Monitoring: Back to the Future Subha L. Varahan, MD, FHRS, CCDS Electrophysiologist Oklahoma Heart Hospital Oklahoma City, OK Friday, February, 8 th, 2019 Iodinated benzofuran
More informationARRHYTHMIAS IN THE ICU: DIAGNOSIS AND PRINCIPLES OF MANAGEMENT
ARRHYTHMIAS IN THE ICU: DIAGNOSIS AND PRINCIPLES OF MANAGEMENT Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS SFGH Division of Cardiogy UCSF CLINICAL VARIABLES IN ARRHYTHMOGENESIS Ischemia/infarction (scar)
More informationComparison of different proarrhythmia biomarkers in isolated rabbit hearts
Comparison of different proarrhythmia biomarkers in isolated rabbit hearts Summary of PhD Thesis Szabolcs Orosz, MSc Supervisor: Attila Farkas MD, PhD 2nd Dept. of Internal Medicine and Cardiology Centre
More informationBoth atrial tachycardia and congestive heart failure (CHF)
Contrasting Efficacy of Dofetilide in Differing Experimental Models of Atrial Fibrillation Danshi Li, MD, PhD; Agnes Bénardeau, PhD; Stanley Nattel, MD Background Rapid atrial pacing (RAP) and congestive
More informationMr. Eknath Kole M.S. Pharm (NIPER Mohali)
M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization
More informationAtrial Fibrillation 10/2/2018. Depolarization & ECG. Atrial Fibrillation. Hemodynamic Consequences
Depolarization & ECG Atrial Fibrillation How to make ORDER out of CHAOS Julia Shih, VMD, DACVIM (Cardiology) October 27, 2018 Depolarization & ECG Depolarization & ECG Atrial Fibrillation Hemodynamic Consequences
More informationChapter 14. Agents used in Cardiac Arrhythmias
Chapter 14 Agents used in Cardiac Arrhythmias Cardiac arrhythmia Approximately 50% of post-myocardial infarction fatalities result from ventricular tachycarida (VT) or ventricular fibrillation (VF). These
More informationARRHYTHMIAS IN THE ICU
ARRHYTHMIAS IN THE ICU Nora Goldschlager, MD MACP, FACC, FAHA, FHRS SFGH Division of Cardiology UCSF IDENTIFIED VARIABLES IN ARRHYTHMOGENESIS Ischemia/infarction (scar) Electrolyte imbalance Proarrhythmia
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationAtrial fibrillation (AF) is a common and troublesome
Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs Akiko Shiroshita-Takeshita, MD; Gernot Schram, MD; Joel Lavoie, PhD; Stanley Nattel,
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationAntiarrhythmic agents in 2014
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Antiarrhythmic agents in 2014 Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice, Italy
More informationTargeting the late sodium channel: A new antiarrhythmic paradigm?
Targeting the late sodium channel: A new antiarrhythmic paradigm? Wojciech Zareba, MD, PhD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Disclosures: - Gilead Sciences:
More informationAtrial repolarizing delaying agents (Vernakalant, Xention)
Atrial repolarizing delaying agents (Vernakalant, Xention) Juan Tamargo, MD, PhD, FESC DISCLOSURES Consulting fees: Sanofi-Aventis, Menarini Department of Pharmacology, School of Medicine Universidad Complutense,
More informationAntiarrhythmic Drugs 1/31/2018 1
Antiarrhythmic Drugs 1/31/2018 1 Normal conduction pathway: 1- SA node generates action potential and delivers it to the atria and the AV node 2- The AV node delivers the impulse to purkinje fibers Other
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More informationCardiac Arrhythmias. For Pharmacists
Cardiac Arrhythmias For Pharmacists Agenda Overview of the normal Classification Management Therapy Conclusion Cardiac arrhythmias Overview of the normal Arrhythmia: definition From the Greek a-, loss
More informationAblation Update and Case Studies. Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group
Ablation Update and Case Studies Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group Disclosures No financial relationships to disclose Objectives At the conclusion of this activity,
More informationDeposited on: 29 October 2009
Workman, A.J. (2009) Mechanisms of postcardiac surgery atrial fibrillation: more pieces in a difficult puzzle. Heart Rhythm, 6 (10). pp. 1423-1424. ISSN 1547-5271 http://eprints.gla.ac.uk/7847/ Deposited
More informationArrhythmias. 1. beat too slowly (sinus bradycardia). Like in heart block
Arrhythmias It is a simple-dysfunction caused by abnormalities in impulse formation and conduction in the myocardium. The heart is designed in such a way that allows it to generate from the SA node electrical
More informationSupplementary Online Content
Supplementary Online Content Verma A, Champagne J, Sapp J, et al. Asymptomatic episodes of atrial fibrillation before and after catheter ablation: a prospective, multicenter study. JAMA Intern Med. Published
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More informationAntiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017
Antiarrhythmic Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017 Types of Cardiac Arrhythmias Abnormalities of Impulse Formation: Rate disturbances. Triggered
More informationAntiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiarrhythmic Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 2 Ion Permeability Changes Potential Changes Genes and Proteins 3 Cardiac Na+ channels 5 6
More informationFibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
More informationThere are future perspectives in the pharmacological treatment of arrhythmias
There are future perspectives in the pharmacological treatment of arrhythmias George Andrikopoulos, MD, PhD, FESC, Cardiologist, Director, 1st Department of Cardiology/ Department of Electrophysiology
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationMechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS)
Mechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS) Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison CSRC-HESI-FDA Rechanneling the Current Cardiac
More informationEHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
More informationUniversity of Groningen. Atrial remodeling due to atrial tachycardia and heart failure Schoonderwoerd, Bas Arjan
University of Groningen Atrial remodeling due to atrial tachycardia and heart failure Schoonderwoerd, Bas Arjan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationAtrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation
Available online at www.sciencedirect.com Journal of Electrocardiology 42 (2009) 543 548 www.jecgonline.com Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation
More informationBlocking the Late Sodium Current
Non-classical Targets in Antiarrhythmic Therapy Blocking the Late Sodium Current Luiz Belardinelli, MD SVP, Cardiovascular Therapeutics Gilead Sciences, CA, USA Madrid June 28, 2011 Disclosures: Full time
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationDifferences in cardiac atrial and ventricular ion channels
Differences in cardiac atrial and ventricular ion channels Norbert Jost, PhD Department of Pharmacology & Pharmacotherapy, University of Szeged Division for Cardiovascular Pharmacology, Hungarian Academy
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationJean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F
SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very
More informationICD THERAPIES: are they harmful or just high risk markers?
ICD THERAPIES: are they harmful or just high risk markers? Konstantinos P. Letsas, MD, PhD, FESC LAB OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL ATHENS ICD therapies are common In a meta-analysis
More informationAtrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation Alexander Burashnikov, PhD, FHRS, Alyssa Petroski, Dan Hu, MD, PhD, Hector Barajas-Martinez,
More informationJ-wave syndromes: update on ventricular fibrillation mechanisms
J-wave syndromes: update on ventricular fibrillation mechanisms Michael Nabauer University of Munich, Germany 28.8.2011 I have no conflicts of interest ECG labelling by Einthoven Circ 1998 Osborn wave
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More informationHow do arrhythmias occur?
How do arrhythmias occur? An arrhythmia is an abnormal heart rhythm (= dysrhythmia). Can be fast (tachy) or slow (brady). Brady arrhythmias are usually due to conduc;on block, while tachyarrhythmias are
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to
More informationDeposited on: 2 April 2009
Workman, A.J. and Pau, D. and Redpath, C. and Marshall, G.E. and Russell, J.A. and Norrie, J. and Kane, K.A. and Rankin, A.C. (29) Atrial cellular electrophysiological changes in patients with ventricular
More informationSupraventricular Tachycardia: From Fetus to Adult. Mohamed Hamdan, MD
Supraventricular Tachycardia: From Fetus to Adult Mohamed Hamdan, MD Learning Objectives Define type of SVT by age Describe clinical approach Describe prenatal and postnatal management of SVT 2 SVT Across
More informationControversies with regard to 'upstream therapy of atrial fibrillation
Controversies with regard to 'upstream therapy of atrial fibrillation Barbara Casadei Department of Cardiovascular Medicine John Radcliffe Hospital University of Oxford No conflict of interest to declare
More informationTdP Mechanisms and CiPA
TdP Mechanisms and CiPA Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison Cardiac Safety Research Consortium Hilton Washington DC December 6, 2016 Disclosures
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationB. 14 Antidysrhythmic drugs. a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification
B. 14 Antidysrhythmic drugs a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification I II III IV membrane stabilizers all ERP, ERP/APD, all except c APD classified
More informationHeart Failure and Atrial Fibrillation
Heart Failure and Atrial Fibrillation 신미승 가천의대심장내과 Prevalence of AF & CHF AF : the most common cardiac arrhythmia more than 2.2 million Americans -- 2007 ACC CHF : more than 5 million Americans The prevalence
More information1. Goette A, et al. J Am Coll Cardiol 2000;35:
Atrial Fibrillation: Upstream Therapies Gerald V. Naccarelli MD M.D. Research support: Boston-Scientific, Sanofi-Aventis, Boehringer-Ingelheim, Glaxo-Smith Smith-Kline Consultant: Glaxo-Smith Smith-Kline,
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationThe unholy trinity of stroke risk: Sleep Apnea, Obesity, and Hypertension
The unholy trinity of stroke risk: Sleep Apnea, Obesity, and Hypertension P. Timothy Pollak, MD, PhD Professor of Medicine, Cardiac Sciences & Pharmacology A Case of Atrial Fibrillation 62 y man referred
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationSHOCK THE PATIENT. Disclosures. Goals of the Talk. Tachyarrhythmias- Unstable 11/7/2017
Disclosures Common Heart Rhythms in the Hospital Research Support: NIH, PCORI, Medtronic, Cardiogram Consulting: InCarda, Johnson & Johnson, Lifewatch Equity: InCarda Gregory M Marcus, MD, MAS Associate
More informationAtrial fibrillation in the ICU
Atrial fibrillation in the ICU Atrial fibrillation Preexisting or incident (new onset) among nearly one in three critically ill patients Formation of arrhythogenic substrate usually fibrosis (CHF, hypertension,
More informationDebate PRO. Dronedarone is an important drug in the management of paroxysmal atrial fibrillation. John Camm
ESC ICM - Internationales Congress Center München 2012 Atrial Fibrillation Controversies in Medical Treatment Debate Dronedarone is an important drug in the management of paroxysmal atrial fibrillation
More informationHow does the heart work? The heart is muscle whose main function is a pump; to push blood the rest of your body.
1 You have a condition called atrial fibrillation. I would like you to learn more about this condition. You should read about it below, and can also watch an Internet program about it. After reading about
More informationArrhythmias. Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium.
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family of disorders that show variety of symptoms, for
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationProgression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro
Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationEctopic Atrial Tachycardia
Europace Madrid, 26-29 June 2011 Ectopic Atrial Tachycardia P. Loh, MD, PhD University of Utrecht Division Heart & Lungs Epidemiology Nonsustained atrial tachycardia Frequent finding on holter registrations
More informationDos and Don t in Cardiac Arrhythmia. Case 1 -ECG. Case 1. Management. Emergency Admissions. Reduction of TE risk -CHADS 2 score. Hospital Admissions
Emergency Admissions Dos and Don t in Cardiac Arrhythmia Tom Wong, MD, FESC Consultant Cardiologist, Honorary Senior Lecturer Royal Brompton & Harefield Hospitals National Heart and Lung Institute, Imperial
More informationArrhythmia Management Joshua M. Cooper, MD, FHRS, FACC
Arrhythmia Management Joshua M. Cooper, MD, FHRS, FACC Professor of Medicine Director of Cardiac Electrophysiology Temple University Health System Plumbing Electrical System Bradyarrhythmias Sinus Node
More informationAPPROACH TO TACHYARRYTHMIAS
APPROACH TO TACHYARRYTHMIAS PROF.DR.MD.ZAKIR HOSSAIN PROFESSOR AND HEAD DEPARTMENT OF MEDICINE SZMCH TACHYARRYTHMIA Cardiac arrythmia is a disturbance of electrical rhythm of heart. Cardac arrythmia with
More informationARRHYTHMIA SINUS RHYTHM
ARRHYTHMIA Dr. Ahmed A. Elberry, MBBCH, MSc, MD Assistant Professor of Clinical Pharmacy Faculty of pharmacy, KAU 1 SINUS RHYTHM SA node is cardiac pacemaker Normal sinus rhythm 60-100 beats/min Depolarisation
More informationManagement of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim
a holistic view - Prof. Dr. Martin Borggrefe Mannheim Patients with atrial fibrillation (millions) 16 14 12 10 8 6 4 2 0 Management of atrial fibrillation Expected prevalence of apparent AF 5,1 5,1 5,9
More informationLecture outline. Electrical properties of the heart. Automaticity. Excitability. Refractoriness. The ABCs of ECGs Back to Basics Part I
Lecture outline The ABCs of ECGs Back to Basics Part I Meg Sleeper VMD, DACVIM (cardiology) University of Florida Veterinary School Electrical properties of the heart Action potentials Normal intracardiac
More informationWorkman, A.J. and Kane, KA. and Rankin, A.C. (2008) Cellular bases for human atrial fibrillation. Heart Rhythm, 5 (6, Supplement). S1-S6.
Workman, A.J. and Kane, KA. and Rankin, A.C. (2008) Cellular bases for human atrial fibrillation. Heart Rhythm, 5 (6, Supplement). S1-S6. http://eprints.gla.ac.uk/4844/ Deposited on: 8 January 2008 Glasgow
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationInteresting EP Cases Catheter ablation to treat congestive heart failure (CHF)
Interesting EP Cases Catheter ablation to treat congestive heart failure (CHF) Yiming WU, MD, PhD. Alaska heart and vascular institute. ywu@alaskaheart.com 907-561-3211 19 yo man transferred for out side
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationDecember D. EL ALLAF Centre Hospitalier Hutois, Huy, Belgium. P. ATTUEL Centre Chirurgical Val d'or, Saint Cloud, France
December 2000 449 European Multicenter Study on the Prevention of Paroxysmal Atrial Fibrillation by Permanent Overdrive Pacing: Atrial Rate Behavior and Patient Tolerance D. EL ALLAF Centre Hospitalier
More informationThe patient with electric storm
The complex patient in the cardiac care unit: The patient with electric storm Helmut U. Klein University of Rochester Medical Center Heart Research Follow-up Program and Isar Heart Center Muenchen Presenter
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationAntiarrhythmic Pharmacology. The Electronics
Antiarrhythmic Pharmacology Linking Pharmacological Treatment to the Patient and the Rhythm Presented By: Karen Marzlin BSN, RN,C, CCRN-CMC CNEA 2009 1 The Electronics Action Potential of Cardiac Cells
More informationLong-Term Atrial Fibrillation Progression: What We Know in 2014
Long-Term Atrial Fibrillation Progression: What We Know in 2014 Advances in Cardiac Arrhythmias and Great Innovations in Cardiology XXVI Giornate Cardiologiche Torinesi Turin, 23-25 October 2014 Davide
More informationNAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010
NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010 I have a financial interest/arrangement or affiliation with
More informationJ Wave Syndromes. Osama Diab Lecturer of Cardiology Ain Shams University
J Wave Syndromes Osama Diab Lecturer of Cardiology Ain Shams University J Wave Syndromes Group of electric disorders characterized by > 1 mm elevation of the J point or prominent J wave with or without
More informationAtrial Fibrillation New Approaches, Techniques, and Technology
New Cardiovascular Horizons 2015 May 28, 2015 New Orleans, Louisiana Atrial Fibrillation New Approaches, Techniques, and Technology State of the Art - - 2015 Richard Abben, M D Director, Cardiac Arrhythmia
More information